The Lynx Group

October 2020, Vol 11, No 5

Capmatinib (Tabrecta), a selective inhibitor of the mesenchymal-epithelial transition (MET) receptor, showed significant antitumor activity in patients with metastatic non–small-cell lung cancer (NSCLC) and gene mutations that lead to MET exon 14 skipping, according to the results of a recently published study.
Read Article

The overall mortality for lung cancer has declined in the United States, but little is known about the mortality trends by lung cancer subtype, because death certificates do not record this information. To address this limitation in the data collection, the Surveillance, Epidemiology, and End Results (SEER) program has linked mortality records to incident cancer cases in all cancer types.
Read Article

The safety and durability of responses to multitargeted inhibitors in thyroid cancer are at least partially limited by side effects. In all, 70% of patients with medullary thyroid cancer carry the RET mutation; RET fusions are rare in other types of thyroid cancer. The efficacy and safety of selective RET inhibition in patients with RET-altered thyroid cancer is unknown.
Read Article

The prognosis of older patients with acute myeloid leukemia (AML) has been poor, even after treatment with a hypomethylating agent. A previous phase 1b study of azacitidine (Vidaza) added to venetoclax (Venclexta) showed promising efficacy and duration of response in treatment-naïve patients with AML who were ineligible for chemotherapy.
Read Article

The combination of carfilzomib (Kyprolis) with lenalidomide (Revlimid) and dexamethasone (KRd) as induction therapy does not improve outcomes in patients newly diagnosed with multiple myeloma compared with the current standard of care with bortezomib (Velcade), lenalidomide, and dexamethasone (VRd).
Read Article

Leading global drug manufacturers have been called on to respond to the COVID-19 pandemic in a myriad of ways; several of their executives discussed those responses in a mid-August webcast from the Association for Value-Based Cancer Care.
Read Article

Patients with cancer and cancer treatment dynamics continue to bounce back toward baseline as of late summer 2020, reported experts at the Association for Value-Based Cancer Care August 20 webcast, which focused on economic trends in cancer care during the COVID-19 pandemic.
Read Article

What are the practical implications of a flurry of recent healthcare-related actions taken by Congress, the Centers for Medicare & Medicaid Services (CMS), and the White House? In summary, “Some can happen, some will take significant effort, but most are just political grandstanding as we get closer to the election,” said Jayson Slotnik, JD, MPH, Partner, Health Policy Strategies, Bethesda, MD, and moderator of the mid-August webcast from the Association for Value-Based Cancer Care.
Read Article

PARP inhibition is moving on from breast and ovarian cancer to the treatment of patients with prostate cancer and BRCA1/2 mutation. Olaparib (Lynparza) reduced the risk for death by 31% versus enzalutamide (Xtandi) or abiraterone (Zytiga) in men with metastatic castration-resistant prostate cancer (CRPC) and BRCA1 or BRCA2, and to a lesser extent ATM mutations, according to the final analysis of the phase 3 PROfound trial.
Read Article

The combination of cabozantinib (Cabometyx), a second-generation tyrosine kinase inhibitor (TKI), plus nivolumab (Opdivo), an immune checkpoint inhibitor, significantly improved overall survival (OS) and doubled the objective response rates (ORR) compared with the current standard, sunitinib (Sutent), in treatment-naïve patients with advanced renal-cell carcinoma (RCC), according to the results of the phase 3 CheckMate-9ER clinical trial. The results were presented at the 2020 European Society for Medical Oncology virtual meeting and were featured at the meeting press conference.
Read Article

Page 2 of 3


Subscribe Today!

To sign up for our newsletter or print publications, please enter your contact information below.

I'd like to receive: